That's a wrap on AACR, and we are leaving the show energized and motivated by the conversations we had and the science our customers are pushing forward.
Last week, we spoke with researchers studying a wide range of cancer-relevant targets and pathways, from mutant proteins like KRAS to cytokines, inflammatory markers, and other signals tied to tumor biology, treatment response, and disease progression. Across those conversations, one theme kept coming through: the biology is complex, and measuring it well still takes real care and reliable reagents.
We heard from scientists working through familiar but important challenges: low-abundance targets, hard-to-measure phosphoforms, complex signaling cascades, and the need for antibodies that work reliably in their samples. These are massive hurdles that shape how quickly and confidently researchers can move a study forward and how much trust they can place in the data along the way.
What stood out most was the level of thought researchers are bringing to these questions. The conversations were not just about finding a target. They were about choosing the right antibody, understanding assay fit, thinking through sample context, and building workflows that are more likely to hold up under real experimental conditions.
That focus is closely aligned with how we think at Aviva. Whether supporting researchers with catalog antibodies, ELISA kits, and proteins, or working on more tailored recombinant antibody and assay development efforts, our goal is to help scientists get to stronger, more reliable measurement.
To everyone who stopped by our booth, shared your research, or talked through a measurement challenge with us - thank you. We are grateful for the chance to learn what you are working on, and we are excited to keep supporting the science ahead.